Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01196858
Other study ID # 2009/1426(REK)
Secondary ID
Status Completed
Phase N/A
First received September 6, 2010
Last updated January 6, 2014
Start date September 2010
Est. completion date September 2013

Study information

Verified date January 2014
Source University Hospital of North Norway
Contact n/a
Is FDA regulated No
Health authority Norway:National Committee for Medical and Health Research EthicsNorway: Norwegian Social Science Data ServicesNorway: Directorate of Health
Study type Observational

Clinical Trial Summary

During the 1990s, evidence began to emerge of the long duration of untreated illness prior to receiving treatment for patients with psychotic disorders. Studies across the world on first episode psychosis have consistently found an average of 1 - 2 years between the onset of psychotic symptoms and the start of treatment. Lengthy treatment delay has immediate implications such as unnecessary distress for patients and families, and may also compromise potential recovery when treatment is initiated.By understanding how and why substantial delays occur the investigators may be able to better design interventions to facilitate better earlier treatment. The components of DUP can be conceptualised as comprising 3 distinct intervals: help-seeking delay, referral delay and delay in mental health services. In this study the primary aim is to establish the level of DUP in nordland, and explore the components of this variable. Help-seeking delay will be investigated by interviewing patients presenting at the central mental health hospital in Nordland about their psychosis onset and pathways to care. Referral delay will be investigated by a questionnaire about the referral pratices among GPs in Nordland. Delays in mental health services will be investigated by focus group interviews with leaders and professionals at the 7 community mental health centers in Nordland. This knowledge is believed to be crucial for developing services that can reduce DUP and give this patient population earlier access to adequate treatment.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date September 2013
Est. primary completion date September 2013
Accepts healthy volunteers No
Gender Both
Age group 16 Years to 35 Years
Eligibility Inclusion Criteria:

- Any patient presenting with a possible psychotic illness (including schizophrenia, affective psychosis and drug-related psychosis, but excluding organic psychosis).

- Understands and speaks norwegian

Exclusion Criteria:

- Severe learning disability

Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


Locations

Country Name City State
Norway Nordland Hospital Trust Bodoe

Sponsors (2)

Lead Sponsor Collaborator
University Hospital of North Norway The Royal Norwegian Ministry of Health

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Duration of untreated psychosis Nottingham Onset Schedule retrospective, lifetime No
See also
  Status Clinical Trial Phase
Completed NCT00136760 - Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia Phase 2
Completed NCT03309475 - Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind) N/A
Not yet recruiting NCT01968161 - Investigator Initiated Study - Asenapine Early Psychosis Phase 4
Completed NCT00135772 - Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2 N/A
Completed NCT02308462 - Implementation and Evaluation of a Family-based Intervention Program for Children of Mentally Ill Parents N/A
Completed NCT03133143 - Video Games Among People With Schizophrenia N/A
Completed NCT00309452 - Specialized Treatment Early in Psychosis (STEP) N/A
Not yet recruiting NCT02240173 - Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia Phase 1/Phase 2
Completed NCT00218218 - Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia Phase 2
Completed NCT02321943 - Anomalous Self-Experience in First Episode Psychosis - A Six-Year Follow-Up Study N/A
Completed NCT02928965 - The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms Phase 2
Completed NCT02307396 - Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients Phase 4
Terminated NCT00748566 - One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome Phase 4
Recruiting NCT00791882 - Social Skills Training in Refractory Schizophrenia N/A
Completed NCT00363181 - Side Effects of Antipsychotic Medications
Completed NCT00137189 - Resource-oriented Music Therapy for Psychiatric Patients With Low Therapy Motivation N/A